Bionomics Limited (NASDAQ:BNOX) Sees Large Growth in Short Interest

Bionomics Limited (NASDAQ:BNOX) was the target of a significant increase in short interest in the month of September. As of September 15th, there was short interest totalling 120,400 shares, an increase of 12.4% from the August 31st total of 107,100 shares. Based on an average daily volume of 901,000 shares, the short-interest ratio is presently 0.1 days.

Bionomics Trading Down 32.0 %

Shares of BNOX opened at $0.44 on Tuesday. Bionomics has a 1-year low of $0.42 and a 1-year high of $5.30. The company has a 50-day moving average of $0.64 and a 200 day moving average of $0.80.

Institutional Trading of Bionomics

A hedge fund recently bought a new stake in Bionomics stock. Armistice Capital LLC acquired a new position in shares of Bionomics Limited (NASDAQ:BNOX) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned 15.03% of Bionomics as of its most recent SEC filing. Institutional investors own 15.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Bionomics in a research report on Thursday, August 1st.

Bionomics Company Profile

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.